fig1
![The impact of rituximab prophylaxis on hepatocellular carcinoma recurrence after living donor liver transplantation](https://image.oaes.cc/ead3b69d-1022-4050-a1f8-f790983bc355/3988.fig.1.jpg)
Figure 1. Standard immunosuppressant protocol for ABO-I (A) from April 2006 to June 2009, (B) from July 2009 to July 2013, and (C) from August 2013. CPA: Cyclophosphamide; HA: hepatic artery; MMF: mycophenolate mofetil; MP: methylprednisolone; PE: plasma exchange; PGE1: prostaglandin E1; PV: portal vein; TAC: tacrolimus; PSL: prednisolone.